AthanassiosArgirisMD

Oncology • Houston, TX

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Professor of Medicine, University Tex San Antonio

Join to view full profile

Dr. Argiris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Argiris' full profile

Already have an account?

Office
1321 Upland Dr
# 4129
Houston, TX 77043
Is this information wrong?

Education & Training

Yale-New Haven Medical CenterFellowship, Medical Oncology, 1999
Icahn School of Medicine at Mount Sinai (Beth Israel)Residency, Internal Medicine, 1994 - 1997
University of AthensClass of 1990

Certifications & Licensure

OH State Medical License Current
TX State Medical License 2011 - 2024
PA State Medical License 2005 - 2024
IL State Medical License 2000 - 2005
CT State Medical License 1997 - 2000

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Fellow (FACP) American College of Physicians, 2005

Clinical Trials

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx Start of enrollment: 1999 Aug 01
Unknown status
Phase 2
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer Start of enrollment: 1999 Aug 01
Unknown status
Phase 1
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer Start of enrollment: 2002 Nov 19
Completed
Phase 2
Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 2
Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Start of enrollment: 2003 May 01
Terminated
Phase 2
Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2003 Jun 01
Completed
Phase 1, Phase 2
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Start of enrollment: 2004 Jun 01
Completed
Phase 2
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer Start of enrollment: 2004 Aug 01
Terminated
Phase 3
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23
Active, not recruiting
Phase 1, Phase 2
Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Start of enrollment: 2006 Oct 01
Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2007 Jun 01
Withdrawn
Phase 2
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC Start of enrollment: 2006 Jun 01
Completed
Phase 2
Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Start of enrollment: 2007 Nov 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Terminated
Phase 2
Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301 Start of enrollment: 2011 Dec 22
Completed
Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies Start of enrollment: 2012 Jul 01
Withdrawn
Phase 2
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with niv...
Mara Serena Serafini, Stefano Cavalieri, Lisa Licitra, Federico Pistore, Deborah Lenoci, Silvana Canevari, Mario Airoldi, Maria Cossu Rocca, Primoz Strojan, Cvetka Gra...> ;Journal for Immunotherapy of Cancer. 2024 Jan 30
A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305.
Flamand, Y., Johnson, J., Vathiotis, I., Levine, M., Li, S., Argiris, A., Savvides, P., Forastiere, A., Burtness, B.> ;European Journal of Cancer. 2024 Mar 1
1 citations
Effect of preoperative programmed death-1 or programmed death ligand-1 immune check point inhibition on complications after surgery for primary head and neck cancer.
Ramez Philips, Dev Amin, Jena Patel, Michael C Topf, Jennifer M Johnson, Voichita BarAd, Rita Axelrod, Athanassios Argiris, Christopher Fundakowski, Adam J Luginbuhl, ...> ;Cancer. 2024 Mar 15
1 citations
Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
Jennifer M Johnson, Ioannis A Vathiotis, Larry A Harshyne, Ayesha Ali, Voichita Bar Ad, Rita Axelrod, Emily Lorber, Joseph Curry, David M Cognetti, Adam J Luginbuhl, M...> ;Journal for Immunotherapy of Cancer. 2023 Aug 1
1 citations
In-Field Toxicity Analysis of a Phase 1 Clinical Trial of Nivolumab and Ipilimumab With Definitive Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the...
Ayesha S Ali, Gregor Manukian, Jennifer M Johnson, Ioannis Vathiotis, Rita Axelrod, Scott W Keith, Joseph Curry, David Cognetti, Adam Luginbuhl, Athanassios Argiris, V...> ;International Journal of Radiation Oncology, Biology, Physics. 2023 Sep 1
24 citations
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of Ch...
Robert I Haddad, Kevin Harrington, Makoto Tahara, Robert L Ferris, Maura Gillison, Jerome Fayette, Amaury Daste, Piotr Koralewski, Bogdan Zurawski, Miren Taberna, Nabi...> ;Journal of Clinical Oncology. 2023 Apr 20
3 citations
CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition.
Joseph Curry, Angela Alnemri, Ramez Philips, Michele Fiorella, Sarah Sussman, Robert Stapp, Charalambos Solomides, Larry Harshyne, Andrew South, Adam Luginbuhl, Madali...> ;The Laryngoscope. 2023 Aug 1
2 citations
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches.
Ioannis A Vathiotis, Jennifer M Johnson, Adam Luginbuhl, David Cognetti, Joseph Curry, Athanassios Argiris> ;Cancer Treatment Reviews. 2022 Sep 1
17 citations
Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.
Adam J Luginbuhl, Jennifer M Johnson, Larry A Harshyne, Alban J Linnenbach, Sanket K Shukla, Angela Alnemri, Gaurav Kumar, David M Cognetti, Joseph M Curry, Nikita Kot...> ;Clinical Cancer Research. 2022 Mar 1
5 citations
Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era.
Nabil F Saba, Jan B Vermorken, Juan P Rodrigo, Stefan M Willems, Nina Zidar, Remco de Bree, Antti Mäkitie, Greg T Wolf, Athanassios Argiris, Yong Teng, Alfio Ferlito, ...> ;Cancers. 2022 Feb 25
9 citations
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort.
Paolo Bossi, Annalisa Trama, Alice Bernasconi, Salvatore Grisanti, Issa Mohamad, Isabel L. Galiana, Enis Ozyar, Pierfrancesco Franco, Stefania Vecchio, Pierluigi Bonom...> ;European Journal of Cancer. 2021 Nov 10
133 citations
Head and neck cancer.
Mayur D Mody, James W Rocco, Sue S Yom, Robert I Haddad, Nabil F Saba> ;Lancet. 2021 Dec 18
34 citations
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
Claire Petit, Benjamin Lacas, Jean-Pierre Pignon, Quynh-Thu Le, Vincent Grégoire, Cai Grau, Allan Hackshaw, Björn Zackrisson, Mahesh K. B. Parmar, Ju-Whei Lee, Maria G...> ;The Lancet. Oncology. 2021 May 1
14 citations
Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
Ioannis A. Vathiotis, Jennifer Johnson, Athanassios Argiris> ;Cancer Treatment Reviews. 2021 Jun 1
10 citations
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer...
Athanassios Argiris, Jieling Miao, Mihaela C. Cristea, Allen M. Chen, Jacob Sands, Roy H. Decker, Scott N. Gettinger, Megan E. Daly, Bryan A. Faller, Kathy S. Albain, ...> ;Clinical Lung Cancer. 2021 Feb 19
124 citations
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
Benjamin Lacas, Alexandra Carmel, Cécile Landais, Stuart J. Wong, Lisa Licitra, Jeffrey S Tobias, Barbara Burtness, Maria Grazia Ghi, Ezra E.W. Cohen, Cai Grau, Gregor...> ;Radiotherapy and Oncology. 2021 Mar 1
4 citations
Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer
Ramez Philips, Chihun Han, Brian Swendseid, Joseph Curry, Athanassios Argiris, Adam Luginbuhl, Jennifer Johnson> ;Frontiers in Oncology. 2021 Jul 1
23 citations
Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment...
Dante J. Merlino, Jennifer Johnson, Madalina Tuluc, Stacey M. Gargano, Robert Stapp, Larry Harshyne, Benjamin E. Leiby, Adam E. Flanders, Ralph Zinner, Rita Axelrod, J...> ;Frontiers in Oncology. 2020 Dec 2
3 citations
Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research...
Laura B. Oswald, Ju Whei Lee, Athanassios Argiris, Kimberly Webster, Arlene A. Forastiere, David Cella> ;Cancer Medicine. 2020 Oct 10
24 citations
An update on angiogenesis targeting in head and neck squamous cell carcinoma.
Ida Micaily, Jennifer Johnson, Athanassios Argiris> ;Cancers of the Head & Neck. 2020 Apr 6
Editorial: Advances in the Systemic Therapy and Combined Modality Approaches for Head and Neck Cancer.
Athanassios Argiris, Lisa Licitra> ;Frontiers in Oncology. 2019 Nov 13
56 citations
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
Athanassios Argiris, Shuli Li, Panayiotis Savvides, James Ohr, Jill Gilbert, Marshall A. Levine, Arnab Chakravarti, Missak Haigentz, Nabil F. Saba, Chukwuemeka Ikpeazu...> ;Journal of Clinical Oncology. 2019 Oct 16
27 citations
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
Leonard Joseph Appleman, Jan H. Beumer, Yixing Jiang, Yan Lin, Fei Ding, Shannon Puhalla, Leigh Swartz, Taofeek K. Owonikoko, R. Donald Harvey, Ronald G. Stoller, Dani...> ;Cancer Chemotherapy and Pharmacology. 2019 Dec 1
16 citations
Laryngeal preservation strategies in locally advanced laryngeal and hypopharyngeal cancers
Athanassios Argiris, Jean Louis Lefebvre> ;Frontiers in Oncology. 2019 May 31
53 citations
Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma.
Gregor Manukian, Voichita Bar-Ad, Bo Lu, Athanassios Argiris, Jennifer Johnson> ;Frontiers in Oncology. 2019 Mar 6
Join now to see all

Lectures

S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell...
2019 ASCO Annual Meeting - 6/1/2019
New Drug, New Setting
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage CancersSeptember 8th, 2021
Northwestern Memorial Hospital Studying Arthritis Drug's Potential in Fighting CancerJuly 3rd, 2003